Response to: ‘Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease’ by Orlando <i>et al</i>

Varkas, Gaëlle; Bosch, Filip Van den; Elewaut, Dirk

doi:10.1136/annrheumdis-2016-211045

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…publications described a number of patients with IBD having possible flares or new occurrence of rheumato logical SpA manifestations after treatment with vedolizumab 250,251 . In another IBD case series, an improvement in rheumatologic manifestations was described with vedolizumab; however, the follow-up period of these cases was very short 252,253 . A post hoc analysis of the phase III vedolizumab trials in IBD (GEMINI trials) indicated that vedolizumab therapy was associated with a reduction in arthritis symptoms in patients with Crohn's disease 254 .…”

Section: Patients With Active Spa and Quiescent Ibdmentioning

confidence: 95%

Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis

et al. 2020

View full text Add to dashboard Cite

Gut inflammation is strongly associated with spondyloarthritis (SpA), as exemplified by the high prevalence of inflammatory bowel disease (IBD) and the even higher occurrence of subclinical gut inflammation in patients with SpA. The gut-joint axis of inflammation in SpA is further reinforced by similarities in immunopathogenesis at both anatomical sites and by the clinical success of therapies blocking TNF and IL-23 in IBD and in some forms of SpA. Many genetic risk factors are shared between SpA and IBD, and changes in the composition of gut microbiota are seen in both diseases. Current dogma is that inflammation in SpA initiates in the gut and leads to joint inflammation; however, although conceptually attractive, some research does not support this causal relationship. For example, therapies targeting IL-17A are efficacious in the joint but not the gut, and interfering with gut trafficking by targeting molecules such as α4β7 in IBD can lead to onset or flares of SpA. Several important knowledge gaps remain that must be addressed in future studies. Determining the true nature of the gut-joint axis has real-world implications for the treatment of patients with co-incident IBD and SpA and for the repurposing of therapeutics from one disease to the other.

show abstract

Section: Patients With Active Spa and Quiescent Ibdmentioning

confidence: 95%

Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis

et al. 2020

View full text Add to dashboard Cite

show abstract

The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights

2021

View full text Add to dashboard Cite

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

Chateau

Bonovas

Berre

et al. 2019

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims We aimed to summarize existing data on the effectiveness of vedolizumab in extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. Methods We conducted a systematic literature search in PubMed and the Cochrane Library, up to October 2018. Interventional and non-interventional studies as well as case-series studying vedolizumab and EIMs in adult patients with IBD were considered eligible. Results Three interventional studies [one randomized trial, n = 1032; and two open-label trials, n = 347], five non-interventional studies [n = 1496] and three case-series [n = 17] were included. Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared to placebo; occurrence was higher, however, with vedolizumab than with tumour necrosis factor inhibitors. Finally, vedolizumab appears not to be efficacious for the treatment of cutaneous manifestations. Conclusions There is no strong evidence to suggest that vedolizumab may be efficacious for the treatment of pre-existing EIMs [especially PSC, rheumatic and cutaneous manifestations], although it may reduce the occurrence of new EIMs.

show abstract

Response to: ‘Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease’ by Orlando et al

Cited by 3 publications

References 7 publications

Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis

Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis

The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights

Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review

Contact Info

Product

Resources

About